Medtronic touts U.S. results of lung cancer detection trial

Partial results of a huge, real-world study of Medtronic’s (NYSE:MDT) superDimension LungGPS technology found that 65% of patients diagnosed with primary lung cancer (Stages I and II) were at early stages of the disease. Early detection of lung cancer is critical to improving patient outcomes long-term. The results came from a 12-month follow-up of the 1,215-patient U.S. portion of the Navigate trial. Begun in 2015, the trial was designed to evaluate the performance of the LungGPS electromagnetic navigation bronchoscopy (ENB) technology that the superDimension device uses to navigate the lungs. Results from the European cohort will be released at a later date, the company said in a statement. Published in The Journal of Thoracic Oncology, the study concluded that ENB-aided diagnosis can be obtained in approximately three-quarters of evaluable patients across a cohort. Navigate enrolled subjects at 37 sites in the U.S. and Europe. Twenty-nine of those sites were in the United States. ENB procedures provide a minimally invasive, GPS-like approach to access difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and potentially lead to earlier, personalized treatment, the company said. Medtronic (Fridley, Minn.) acquired the superDimension lung device as part of its 2015 purchase of  Dublin, Ireland-based Covidien. According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in the United States. Most...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Clinical Trials Featured Oncology Covidien journalofthoraciconcology Medtronic Source Type: news